GLORIA is an international investigator – initiated trial aiming to prove (or disprove) that the addition of chronic low dose glucocorticoids to current anti-rheumatic therapy is cost-effective and safe, in elderly patients with Rheumatoid Arthritis (RA). About 50% of patients are currently treated with this strategy.

GLORIA is funded by the EU Horizon 2020 Program. >> 


The "official view" on glucocorticoids in rheumatoid arthritis - a systematic review of international guidelines and consensus statements

OBJECTIVE: To describe the perception on the current role of systemic glucocorticoids (GC) in the management of rheumatoid arthritis (RA) by examining their importance and the current level of evidence in recent guidelines, and to identify open questions to be addressed in future guidelines and research projects. METHODS: Systematic literature review using the databases PubMed, EMBASE and
Read more

In Excelsis: The GLORIA Consortium Submits EU-Horizon Proposal for a New Trial and Project

We are pleased to announce that we have submitted an EU-Horizon 2020 proposal for a new trial and project to complement GLORIA. In Call PM10, the EU requested proposals for studies "evaluating existing health care in the adult population”. The call text was almost identical to the call text on the elderly in which GLORIA was successful. As more than half of the RA population is no
Read more

First patient included

It is with great pleasure that we announce that the first patient has now been included in GLORIA trial. The patient was included in VU University Medical Center, Amsterdam, Netherlands. GLORIA trial finally has lift off!
Read more